|
|
||||||||
,


,
* Vita-Salute University and Stem Cell Research Institute, San Raffaele, Milan, Italy;
Department of Preclinical Sciences, University of Milan, Milan, Italy;
E. Medea Scientific Institute, Bosisio Parini, Italy; and
Department of Pharmaco-Biology, University of Calabria, Rende, Italy
Depletion of dendritic cells (DCs) via apoptosis contributes to sepsis-induced immune suppression. The mechanisms leading to DC apoptosis during sepsis are not known. In this study we report that immature DCs undergo apoptosis when treated with high numbers of Escherichia coli. This effect was mimicked by high concentrations of LPS. Apoptosis was accompanied by generation of ceramide through activation of acid sphingomyelinase (A-SMase), was prevented by inhibitors of this enzyme, and was restored by exogenous ceramide. Compared with immature DCs, mature DCs expressed significantly reduced levels of A-SMase, did not generate ceramide in response to E. coli or LPS, and were insensitive to E. coli- and LPS-triggered apoptosis. However, sensitivity to apoptosis was restored by addition of exogenous A-SMase or ceramide. Furthermore, inhibition of A-SMase activation and ceramide generation was found to be the mechanism through which the immune-modulating messenger NO protects immature DCs from the apoptogenic effects of E. coli and LPS. NO acted through formation of cGMP and stimulation of the cGMP-dependent protein kinase. The relevance of A-SMase and its inhibition by NO/cGMP were confirmed in a mouse model of LPS-induced sepsis. DC apoptosis was significantly higher in inducible NO synthase-deficient mice than in wild-type animals and was significantly reduced by treatment ex vivo with NO, cGMP, or the A-SMase inhibitor imipramine. Thus, A-SMase plays a central role in E. coli/LPS-induced DC apoptosis and its inhibition by NO, and it might be a target of new therapeutic approaches to sepsis.
This article has been cited by other articles:
![]() |
C. Perrotta, L. Bizzozero, S. Falcone, P. Rovere-Querini, A. Prinetti, E. H. Schuchman, S. Sonnino, A. A. Manfredi, and E. Clementi Nitric Oxide Boosts Chemoimmunotherapy via Inhibition of Acid Sphingomyelinase in a Mouse Model of Melanoma Cancer Res., August 15, 2007; 67(16): 7559 - 7564. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Lasarte, N. Casares, M. Gorraiz, S. Hervas-Stubbs, L. Arribillaga, C. Mansilla, M. Durantez, D. Llopiz, P. Sarobe, F. Borras-Cuesta, et al. The Extra Domain A from Fibronectin Targets Antigens to TLR4-Expressing Cells and Induces Cytotoxic T Cell Responses In Vivo J. Immunol., January 15, 2007; 178(2): 748 - 756. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Albee, B. Shi, and H. Perlman Aspartic protease and caspase 3/7 activation are central for macrophage apoptosis following infection with Escherichia coli J. Leukoc. Biol., January 1, 2007; 81(1): 229 - 237. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Sciorati, B. G. Galvez, S. Brunelli, E. Tagliafico, S. Ferrari, G. Cossu, and E. Clementi Ex vivo treatment with nitric oxide increases mesoangioblast therapeutic efficacy in muscular dystrophy J. Cell Sci., December 15, 2006; 119(24): 5114 - 5123. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Giordano, D. M. Magaletti, and E. A. Clark Nitric oxide and cGMP protein kinase (cGK) regulate dendritic-cell migration toward the lymph-node-directing chemokine CCL19 Blood, February 15, 2006; 107(4): 1537 - 1545. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Morita, T. Uchiyama, and T. Hori Nitric Oxide Inhibits IFN-{alpha} Production of Human Plasmacytoid Dendritic Cells Partly via a Guanosine 3',5'-Cyclic Monophosphate-Dependent Pathway J. Immunol., July 15, 2005; 175(2): 806 - 812. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |